Successful treatment of a patient with mitochondrial myopathy with alirocumab.

Abstract

A 48-year-old man presented to our lipid clinic with statin intolerance and elevated serum creatine kinase levels, being affected by mitochondrial myopathy because of heteroplasmic mitochondrial DNA missense mutation in MTCO1 gene (m.7671T>A). He had just been treated with a coronary artery bypass 4 years before because of acute coronary syndrome, and he had consistently high levels of both low-density lipoprotein cholesterol and triglycerides. Dyslipidemia was successfully treated using 75 mg of alirocumab subcutaneously every 2 weeks, 10 mg of ezetimibe daily, 2 g of marine omega-3 fatty acids daily, and 145 mg of micronized fenofibrate every 2 days. Although muscle weakness persisted, myalgia did not reoccur and serum creatine kinase levels remained almost stable over the time.

• Authors: Arrigo F G Cicero, Federica Fogacci, Marilisa Bove, Claudio Borghi
• Journal: Journal of clinical lipidology (J Clin Lipidol) 2020 Sep - Oct Vol. 14 Issue 5 Pg. 646-648 ISSN: 1933-2874 [Print] United States
• PMID: 32800583 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2020 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Chemical References

• Antibodies, Monoclonal, Humanized
• Electron Transport Complex IV
• cytochrome c oxidase subunit I, human
• alirocumab

Topics

• Antibodies, Monoclonal, Humanized (therapeutic use)
• Electron Transport Complex IV (genetics, metabolism)
• Humans
• Hyperlipidemias (drug therapy, metabolism, pathology)
• Male
• Middle Aged
• Mitochondrial Myopathies (drug therapy, metabolism, pathology)
• Mutation, Missense
• Prognosis